Cargando…

A fluorescence-based, gain-of-signal, live cell system to evaluate SARS-CoV-2 main protease inhibition

The likelihood of continued circulation of COVID-19 and its variants, and novel coronaviruses due to future zoonotic transmissions, combined with the current paucity of coronavirus antivirals, emphasize the need for improved screening in developing effective antivirals for the treatment of infection...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dey-Rao, Rama, Smith, George R., Timilsina, Uddhav, Falls, Zackary, Samudrala, Ram, Stavrou, Spyridon, Melendy, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Author(s). Published by Elsevier B.V. 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8495046/ https://www.ncbi.nlm.nih.gov/pubmed/34626674 http://dx.doi.org/10.1016/j.antiviral.2021.105183

Ejemplares similares

Shotgun drug repurposing biotechnology to tackle epidemics and pandemics
por: Mangione, William, et al.
Publicado: (2020)

Shotgun drug repurposing biotechnology to tackle epidemics and pandemics
por: Mangione, William, et al.
Publicado: (2020)

Accurate Prediction of Inhibitor Binding to HIV-1 Protease Using CANDOCK
por: Falls, Zackary, et al.
Publicado: (2022)

SERINC5: One antiviral factor to bind them all
por: Timilsina, Uddhav, et al.
Publicado: (2023)

SARS-CoV-2 ORF7a potently inhibits the antiviral effect of the host factor SERINC5
por: Timilsina, Uddhav, et al.
Publicado: (2022)

Determining the antiviral mechanism of MARCH2
por: Umthong, Supawadee, et al.
Publicado: (2023)

Optimal COVID-19 therapeutic candidate discovery using the CANDO platform
por: Mangione, William, et al.
Publicado: (2022)

Effective holistic characterization of small molecule effects using heterogeneous biological networks
por: Mangione, William, et al.
Publicado: (2023)

SERINC5 Potently Restricts Retrovirus Infection In Vivo
por: Timilsina, Uddhav, et al.
Publicado: (2020)

Exploration of interaction scoring criteria in the CANDO platform
por: Falls, Zackary, et al.
Publicado: (2019)

A Deep-Learning Proteomic-Scale Approach for Drug Design
por: Overhoff, Brennan, et al.
Publicado: (2021)

Elucidating the Antiviral Mechanism of Different MARCH Factors
por: Umthong, Supawadee, et al.
Publicado: (2021)

352 Computational methods for predicting drug combinations for targeting KRAS mutations relevant to non-small cell lung cancer
por: Bruggemann, Liana, et al.
Publicado: (2022)

Association of C>U RNA Editing with Human Disease Variants
por: MANDLOI, Sapan, et al.
Publicado: (2020)

Evaluating the performance of drug-repurposing technologies
por: Schuler, James, et al.
Publicado: (2022)

Identifying Protein Features and Pathways Responsible for Toxicity Using Machine Learning and Tox21: Implications for Predictive Toxicology
por: Moukheiber, Lama, et al.
Publicado: (2022)

SARS-CoV-2 main protease targeting potent fluorescent inhibitors: Repurposing thioxanthones
por: BATIBAY, Gönül S., et al.
Publicado: (2023)

The Role of C-to-U RNA Editing in Human Biodiversity
por: Van Norden, Melissa, et al.
Publicado: (2023)

Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
por: Kuang, Yi, et al.
Publicado: (2023)

Activation and maturation of SARS-CoV main protease
por: Xia, Bin, et al.
Publicado: (2011)

Multiscale Analysis and Validation of Effective Drug Combinations Targeting Driver KRAS Mutations in Non-Small Cell Lung Cancer
por: Bruggemann, Liana, et al.
Publicado: (2023)

Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332
por: Zhao, Yao, et al.
Publicado: (2021)

The SARS-CoV-2 main protease as drug target
por: Ullrich, Sven, et al.
Publicado: (2020)

Topological analysis of SARS CoV-2 main protease
por: Estrada, Ernesto
Publicado: (2020)

Potential SARS-CoV-2 main protease inhibitors
por: Banerjee, Riddhidev, et al.
Publicado: (2021)

Developing inhibitors of the SARS-CoV-2 main protease
por: Seitz, Christian, et al.
Publicado: (2022)

Allosteric Hotspots in the Main Protease of SARS-CoV-2
por: Strömich, Léonie, et al.
Publicado: (2022)

Allosteric inhibitors of the main protease of SARS-CoV-2
por: Samrat, Subodh Kumar, et al.
Publicado: (2022)

Impact of Drug Repurposing on SARS-Cov-2 Main Protease
por: Ndagi, Umar, et al.
Publicado: (2023)

Analysis of the efficacy of HIV protease inhibitors against SARS-CoV-2′s main protease
por: Mahdi, Mohamed, et al.
Publicado: (2020)

Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives
por: Amporndanai, Kangsa, et al.
Publicado: (2021)

Biochemical screening for SARS-CoV-2 main protease inhibitors
por: Coelho, Camila, et al.
Publicado: (2020)

Structure of SARS-CoV-2 main protease in the apo state
por: Zhou, Xuelan, et al.
Publicado: (2020)

Correlation between dissociation and catalysis of SARS-CoV main protease
por: Lin, Pei-Ying, et al.
Publicado: (2008)

Copper(II) Inhibition of the SARS-CoV-2 Main Protease
por: Garza-López, Roberto A., et al.
Publicado: (2020)

Discovery and Mechanism of SARS-CoV-2 Main Protease Inhibitors
por: Huff, Sarah, et al.
Publicado: (2021)

Fullerene derivatives as inhibitors of the SARS-CoV-2 main protease
por: Katagishi, Daiki, et al.
Publicado: (2023)

Optimization of the expression of the main protease from SARS-CoV-2
por: Rong, Yi, et al.
Publicado: (2023)

Potent and biostable inhibitors of the main protease of SARS-CoV-2
por: Tsuji, Kohei, et al.
Publicado: (2022)

Insights into the structural properties of SARS-CoV-2 main protease
por: Akbayrak, Ibrahim Yagiz, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rm683v9dnph55d09af3egafcis